Ubs Global Asset Management Americas Increased Its Scansource (SCSC) Position; Clovis Oncology (CLVS) Shorts Up By 1.56%

January 14, 2018 - By Adrian Erickson

Ubs Global Asset Management Americas Inc increased Scansource Inc (SCSC) stake by 0.6% reported in 2017Q3 SEC filing. Ubs Global Asset Management Americas Inc acquired 101 shares as Scansource Inc (SCSC)’s stock declined 12.70%. The Ubs Global Asset Management Americas Inc holds 16,992 shares with $741.70 million value, up from 16,891 last quarter. Scansource Inc now has $908.75 million valuation. It closed at $35.65 lastly. It is down 0.87% since January 14, 2017 and is downtrending. It has underperformed by 17.57% the S&P500.

Clovis Oncology Incorporated (NASDAQ:CLVS) had an increase of 1.56% in short interest. CLVS’s SI was 7.06 million shares in January as released by FINRA. Its up 1.56% from 6.95 million shares previously. With 1.19M avg volume, 6 days are for Clovis Oncology Incorporated (NASDAQ:CLVS)’s short sellers to cover CLVS’s short positions. The SI to Clovis Oncology Incorporated’s float is 22.77%. The stock decreased 1.54% or $0.92 during the last trading session, reaching $59.01. About 1.52M shares traded or 26.82% up from the average. Clovis Oncology, Inc. (NASDAQ:CLVS) has risen 282.71% since January 14, 2017 and is uptrending. It has outperformed by 266.01% the S&P500.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has market cap of $2.89 billion. The Company’s commercial product includes Rubraca tablet, an oral and small molecule poly ADP-ribose polymerase inhibitor as monotherapy for the treatment of patients with deleterious breast cancer mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. It currently has negative earnings. The firm is also involved in the ARIEL3 and ARIEL4 confirmatory trials of rucaparib as a potential maintenance therapy and treatment for ovarian cancer; trial of rucaparib in prostate indications (TRITON) 2, a Phase 2 single-arm study in men with metastatic castrate-resistant prostate cancer; and TRITON3, a Phase 3 comparative study in men with mCRPC enrolling BRCA mutant and ATM, as well as engages in the various clinical studies for other indications.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 14 have Buy rating, 0 Sell and 6 Hold. Therefore 70% are positive. Clovis Oncology had 54 analyst reports since September 10, 2015 according to SRatingsIntel. The company was maintained on Wednesday, August 24 by Mizuho. The rating was maintained by Suntrust Robinson on Friday, September 23 with “Buy”. The rating was maintained by Piper Jaffray with “Neutral” on Monday, November 16. The firm has “Buy” rating given on Tuesday, July 18 by Credit Suisse. Goldman Sachs downgraded the shares of CLVS in report on Tuesday, November 17 to “Neutral” rating. The firm earned “Overweight” rating on Thursday, November 2 by Morgan Stanley. The firm earned “Outperform” rating on Wednesday, September 21 by Credit Suisse. J.P. Morgan maintained the shares of CLVS in report on Thursday, June 1 with “Buy” rating. As per Thursday, January 26, the company rating was upgraded by Piper Jaffray. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) has “Hold” rating given on Thursday, November 2 by RBC Capital Markets.

Since August 4, 2017, it had 0 buys, and 6 sales for $2.61 million activity. IVERS-READ GILLIAN C also sold $208,500 worth of Clovis Oncology, Inc. (NASDAQ:CLVS) shares. Another trade for 18,450 shares valued at $1.45 million was made by BLAIR JAMES C on Friday, August 4. SPICKSCHEN THORLEF had sold 4,500 shares worth $292,365 on Monday, January 8.

Investors sentiment decreased to 1.44 in 2017 Q3. Its down 0.37, from 1.81 in 2017Q2. It dropped, as 48 investors sold Clovis Oncology, Inc. shares while 49 reduced holdings. 42 funds opened positions while 98 raised stakes. 47.46 million shares or 2.14% more from 46.46 million shares in 2017Q2 were reported. Plante Moran Finance Llc holds 0% in Clovis Oncology, Inc. (NASDAQ:CLVS) or 57 shares. Price T Rowe Md reported 1.35M shares or 0.02% of all its holdings. Kingdon Cap Mgmt Limited Co invested 0.84% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). The Virginia-based Bb&T Ltd Com has invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). Federated Investors Inc Pa stated it has 10,000 shares. Moreover, First Mercantile Company has 0.1% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 6,844 shares. Castleark Limited Liability Com invested in 61,625 shares. Nokota Mngmt Lp stated it has 0.21% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). The Texas-based Hbk Invests Lp has invested 0.02% in Clovis Oncology, Inc. (NASDAQ:CLVS). Zurcher Kantonalbank (Zurich Cantonalbank) reported 1,819 shares stake. Columbus Circle has 213,674 shares. Ameritas Invest Ptnrs has 3,725 shares. Rice Hall James And Associate Llc has invested 0.44% in Clovis Oncology, Inc. (NASDAQ:CLVS). Raymond James Svcs Advsrs holds 12,465 shares. Fisher Asset Management Limited Liability Corp reported 0% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS).

Among 2 analysts covering ScanSource (NASDAQ:SCSC), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ScanSource had 3 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of ScanSource, Inc. (NASDAQ:SCSC) earned “Outperform” rating by Raymond James on Tuesday, August 30. The stock of ScanSource, Inc. (NASDAQ:SCSC) earned “Buy” rating by Northcoast on Wednesday, December 23. The company was upgraded on Wednesday, August 12 by Zacks.

Since September 18, 2017, it had 0 insider purchases, and 3 selling transactions for $2.58 million activity. 9,076 ScanSource, Inc. (NASDAQ:SCSC) shares with value of $370,590 were sold by Reilly John Patrick. 5,435 shares valued at $238,053 were sold by BAUR MICHAEL L on Monday, October 9.

Ubs Global Asset Management Americas Inc decreased Tech Data Corp (NASDAQ:TECD) stake by 10,823 shares to 48,228 valued at $4.29B in 2017Q3. It also reduced Omnicell Inc (NASDAQ:OMCL) stake by 2,266 shares and now owns 160,124 shares. Textron Inc (NYSE:TXT) was reduced too.

Investors sentiment increased to 1.26 in 2017 Q3. Its up 0.23, from 1.03 in 2017Q2. It is positive, as 11 investors sold SCSC shares while 47 reduced holdings. 20 funds opened positions while 53 raised stakes. 23.93 million shares or 1.00% more from 23.70 million shares in 2017Q2 were reported. Pzena Investment Mgmt Llc has 0.3% invested in ScanSource, Inc. (NASDAQ:SCSC) for 1.32M shares. Federated Investors Pa reported 592 shares. Cornercap Invest Counsel Inc stated it has 19,995 shares. Martingale Asset Management LP has 155,339 shares. Teachers Retirement Of The State Of Kentucky stated it has 9,500 shares or 0% of all its holdings. Fenimore Asset owns 0.53% invested in ScanSource, Inc. (NASDAQ:SCSC) for 305,070 shares. Northern Tru Corporation has invested 0.01% in ScanSource, Inc. (NASDAQ:SCSC). Legal General Group Inc Public Limited Company holds 0% or 72,600 shares. Tower Capital Limited Liability Corp (Trc) holds 3,601 shares. Kennedy Capital Management Inc, a Missouri-based fund reported 121,247 shares. Barrow Hanley Mewhinney Strauss Limited Co invested in 0.01% or 141,054 shares. Metropolitan Life Ins has invested 0% of its portfolio in ScanSource, Inc. (NASDAQ:SCSC). Jpmorgan Chase And has invested 0% in ScanSource, Inc. (NASDAQ:SCSC). 39,688 are owned by Wells Fargo & Mn. Menta Capital Ltd Liability Com reported 0.18% in ScanSource, Inc. (NASDAQ:SCSC).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>